Mr Ho Sheng
Mr Ho Sheng was first appointed as a Director of the Company in July 2011 and was last re-elected on October 16, 2015. He was re-designated as Chairman of the Board in November 2016.
Mr Ho has more than 25 years of experience in the financial services industry, especially in Asia’s equity markets. He is also the Non-Executive Chairman and Independent Director of New Silkroutes Group Limited, which is listed on the Singapore Exchange.
Mr Ho was previously an Independent Director at Ying Li International Real Estate Limited and Senior Vice President of Investments at Citigroup Global Markets. Prior to joining Citigroup, he was a shareholder, Executive Director and Board Member of the stockbroking unit of UBS Warburg.
Mr Ho holds a Master of Applied Finance from Macquarie University, Sydney. He is a Senior Associate of the Financial Services Institute of Australasia and an Associate of the Institute of Chartered Secretaries and Administrators (UK).
Dr Ho Choon Hou
Dr Ho Choon Hou was frst appointed as a Director of the Company in June 2011 and was last re-elected on October 28, 2016.
Dr Ho is a Principal at Southern Capital Group Limited, where he is responsible for the origination and execution of investments, as well as an Independent Director of Advanced Holdings Limited and Mclean Berhad. Dr Ho holds a Bachelor of Medicine and Bachelor of Surgery (Honours) from the University of Sheffeld, as well as a Master of Medicine (Surgery) from the National University of Singapore and a Master of Business Administration (Honours) from the University of Chicago (Graduate School of Business).
Dr Wong Chiang Yin
Dr Wong Chiang Yin was appointed as Executive Director and Group Chief Executive Offcer (outgoing*) of the Company on July 1, 2016 and was last re-elected on October 28, 2016. He is responsible for identifying and implementing company-wide business growth strategies and organisational structures, and directly oversees all aspects of the Group’s growth and operating functions. Dr Wong is a medical doctor and a public health specialist with more than 20 years of healthcare management experience. Prior to joining the Group, he was the Executive Director and Group CEO of TMC Life Sciences Bhd., a healthcare company listed on the mainboard of Bursa Malaysia. He was concurrently the President of Thomson International, the international arm of Thomson Medical Centre, Singapore’s largest private obstetrics and gynaecology hospital.
Between 2008 and 2009, Dr Wong was the Executive Director and CEO of the Hospitals Division in Pantai Holdings Berhad. Prior to joining the private sector in 2008, he was the Chief Operating Offcer of Changi General Hospital and Singapore General Hospital, as well as the Director of Business Development at SingHealth.
Dr Wong has held, and still holds, leadership positions in various medical professional bodies. He has been a council member of the Singapore Medical Association for over 20 years, and was its president from 2006 to 2009. He has also been a council member of the Academy of Medicine Singapore since 2009.
Dr Wong is currently an Independent Director of Beng Kuang Marine Limited, a company listed on the Singapore Exchange. He is also the Chairman of the Citizens’ Consultative Committee of the Holland-Bukit Timah Group Representation Constituency, Cashew Division.
Dr Wong holds a Bachelor of Medicine and Bachelor of Surgery, as well as a Master of Medicine (Public Health) from the National University of Singapore. He also holds a Master of Business Administration (Finance) from the University of Leicester. He is a Fellow of the Academy of Medicine, Singapore.
Mr Michael Steven Weiss
Mr Michael Steven Weiss serves as Group Chief Executive Officer (appointed on February 12, 2018) and Executive Director, Business Development and Mergers & Acquisitions (appointed on February 1, 2017) for the Group. Prior to his re-designation, he was appointed as a Non-Independent, Non-Executive Director of the Company on November 1, 2016.
Mr Weiss has over 20 years of experience in the finance and investment sectors in North America and Asia, and has served on several investment committees and corporate boards, including those of healthcare companies, where he advised CEOs and CFOs on strategic initiatives, human resource management, financial planning and public and private capital raising.
Prior to his current positions, Mr Weiss was a Partner and Managing Director at cross-border private equity firm, Sailing Capital, China’s largest RMB overseas investment fund. He also served as Managing Director of Morgan Stanley’s China mergers advisory unit and held investment banking positions at Credit Suisse Group and Citigroup, where he executed over $20 billion in M&A and capital markets transactions.
Mr Weiss obtained his Master of Arts in Regional Studies East Asia, focusing on Chinese business history, from Harvard University. He also holds a Bachelor degree in East Asian Studies from Northwestern University and is ﬂuent in Mandarin Chinese.
Dr Goh Jin Hian
Dr Goh Jin Hian was first appointed as a Director of the Company in July 2011 and was last re-elected on October 28, 2016.
He is also currently an Executive Director and Chief Executive Officer of New Silkroutes Group, which is an SGX-listed company. Prior to joining New Silkroutes Group, Dr Goh was a C-suite executive in Parkway Health from 1999-2011 and an Executive Director in a private oil and gas company from 2012 – 2014.
He had also served on the Council of Singapore Human Resource Institute from 2007 to 2017 and on the Council of the Singapore Medical Association from 1996 to 2000.
Dr Goh obtained his Bachelor of Medicine and Bachelor of Surgery from the National University of Singapore in 1992. He also holds a Master of Business Administration from the University of Hull. In addition, Dr Goh completed The Wharton Advanced Management Program in 2005.
Mr Joseph Wong Wai Leung
Mr Joseph Wong Wai Leung was appointed as an Independent Director of the Company on September 23, 2014 and was last re-elected on October 17, 2014.
Mr Wong has a wealth of experience in the financial services industry. He started his career at Big Four auditing firms PricewaterhouseCoopers and Deloitte Touche Tohmatsu, Hong Kong (“Deloitte”).
At Deloitte, he was engaged in a wide spectrum of business domains, including initial public offerings, taxation, and asset protection plans for high net worth individuals. Subsequently, he worked at Credit Agricole (Suisse), Hong Kong, where he advised clients on wealth management.
Mr Wong holds a Bachelor of Commerce from the University of Calgary in Alberta, Canada.
Mr Chen Bing Chuen, Albert
Mr Albert Chen was appointed as a Non-Independent, Non-Executive Director of the Company on April 29, 2016 and was last re-elected on October 28, 2016.
Mr Chen is the Chief Financial Officer and Director of NYSE-listed China Cord Blood Corporation (“CCBC”), where he oversees finance-related matters including accounting and budget planning. He is also involved in CCBC’s corporate structuring and development, including mergers and acquisitions, and investment in foreign healthcare companies.
Mr Chen had previously served as the vice-president of corporate finance at Golden Meditech Holdings Limited since March 2005, prior to which he worked in financial institutions such as Salomon Smith Barney, DBS Vickers Securities and UOB Kay Hian in Hong Kong.
Mr Chen is a CFA charterholder. He holds a Bachelor in Commerce from Queen’s University in Canada, with a major in Finance and Accounting.
Ms Wong Christine Bei
Ms Christine Wong was appointed as a Non-Independent, Non-Executive Director of the Company on November 1, 2016.
Ms Wong has been the Senior Investment Director of Kunlum Investment Holding Limited ("Kunlum") since November 2015. Prior to joining Kunlum, she was the Managing Director at CBW Consulting, Inc. (“CBW”) for 10 years. CBW is a consulting firm that focuses on United States-China relations and business projects.
Ms Wong holds a Bachelor in Business Administration from Hofstra University.
Ms Wang Tongyan
Ms Wang Tongyan was appointed as a Non-Independent, Non-Executive Director of the Company on May 4, 2017.
Ms Wang has more than 22 years of experience in the pharmaceutical industry, specialising in market management. She is currently the Vice President of Sanpower Group (“Sanpower”), where she oversees biomedical group strategies and medical industry management. Prior to joining Sanpower, she was the Vice President of Image Innovation at Nanchang China Sciences Group and Chief Operating Officer at CSG Jiufeng Mobile Health Care Co., Ltd.
Ms Wang previously also served as the Vice President of Janssen Pharmaceutical Co., Ltd of US Johnson & Johnson Group, where she was Chief Marketing Officer and sales director. She also holds various public posts, such as Vice President of the China Pharmaceutical Industry Association.
Ms Wang holds a PhD in theoretical research from the University of Lisbon, as well as a Master in Business Administration and a Bachelor of Clinical Medicine from Xi’an Jiaotong University.